SL-401: An Encouraging Option for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

Monday, June 6, 2016

Naveen Pemmaraju, MD, discusses early results from an ongoing trial of SL-401 in patients with the rare, aggressive malignancy blastic plasmacytoid dendritic cell neoplasm.

Focus on Classical Hematology (Volume 5, Issue 12.1)

October 2019, Volume 5, Issue 12

September 2019, Volume 5, Issue 11

August 2019, Volume 5, Issue 10

SL-401: An Encouraging Option for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

Recent Articles

Trump to Nominate Stephen Hahn as FDA Commissioner

FDA Warns of Cybersecurity Vulnerabilities in Medical Devices

Trump Administration Renews Efforts to Dismantle the Affordable Care Act

Nobel Prize Awarded for Discovery of How Cells Sense Oxygen

U.K. Labour Party Plans to Regulate Pharmaceutical Market, Lower Drug Prices

Current Issue

October 2019, Volume 5, Issue 12

Meeting Coverage

Non-Engineered T Cells to Prevent or Treat Relapse in Post-Transplant AML/MDS

RADIUS: Midostaurin Reduces Post-Transplant Relapse Risk in FLT3-Mutated AML

Editor`s Corner

Fathers (and Mothers) of Hematology

Our Identity Crisis